Review

A$_{2B}$ Adenosine Receptor and Cancer

Zhan-Guo Gao * and Kenneth A. Jacobson *

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0810, USA

* Correspondence: zg21o@nih.gov (Z.-G.G.); kennethJ@niddk.nih.gov (K.A.J.);
  Tel.: +1-301-402-3776 (Z.-G.G.); +1-301-496-9024 (K.A.J.)

check for
updates

Abstract: There are four subtypes of adenosine receptors (ARs), named A$_1$, A$_{2A}$, A$_{2B}$ and A$_3$, all of which are G protein-coupled receptors (GPCRs). Locally produced adenosine is a suppressant in anti-tumor immune surveillance. The A$_{2B}$AR, coupled to both Gαs and Gαi G proteins, is one of the several GPCRs that are expressed in a significantly higher level in certain cancer tissues, in comparison to adjacent normal tissues. There is growing evidence that the A$_{2B}$AR plays an important role in tumor cell proliferation, angiogenesis, metastasis, and immune suppression. Thus, A$_{2B}$AR antagonists are novel, potentially attractive anticancer agents. Several antagonists targeting A$_{2B}$AR are currently in clinical trials for various types of cancers. In this review, we first describe the signaling, agonists, and antagonists of the A$_{2B}$AR. We further discuss the role of the A$_{2B}$AR in the progression of various cancers, and the rationale of using A$_{2B}$AR antagonists in cancer therapy.

Keywords: adenosine receptor; immune system; cancer therapy; tumor microenvironment; cell proliferation; metastasis

1. Introduction

Adenosine, in the extracellular milieu, is generated mainly via the degradation of adenosine 5′-triphosphate (ATP) released under stress conditions, to protect cells and tissues locally. Adenosine and ATP acting at different classes of receptors often have opposite effects in cell proliferation or cell death. ATP and other adenine nucleotides have antitumor effects via the activation of the P2Y$_1$ receptor (P2Y$_1$R) subtype [1,2], whereas adenosine induces cancer cell proliferation and growth of many types of tumors via the activation of the A$_{2B}$ adenosine receptor (AR) [3–10]. The generation and degradation/removal of adenosine is a multi-step and balanced process in cells involving enzymes (Cluster of Differentiation 39 (CD39), CD73, CD26, adenosine deaminase, adenosine kinase, S-adenosyl homocysteine hydrolase) and nucleoside transporters [11], which are not the main topic of this review. Although extracellular adenosine exerts its action via four G protein-coupled receptors (GPCRs), A$_1$, A$_{2A}$, A$_{2B}$ and A$_3$ [12], in this review we will only focus on the importance of A$_{2B}$AR signaling (Figure 1) in cancer progression and the rationale to use A$_{2B}$AR antagonists as anticancer agents.

The importance of the A$_{2B}$AR in cancer progression has only recently been revealed, despite the physiological role of adenosine in cardiac function being realized almost a century ago [13]. Although A$_{2B}$AR effects in brain slices were characterized in the early 1980s [14], until recently the A$_{2B}$AR has been poorly characterized in comparison to the other three ARs, which is at least in part due to the fact that A$_{2B}$AR has low affinity for the endogenous agonist adenosine 1 (EC$_{50}$ ~24 µM, Figure 2, Table 1). Thus, it was assumed that A$_{2B}$AR must have a minor physiological significance. However, increasing evidence has shown that there is a dramatic increase in extracellular adenosine concentration and a significant upregulation of A$_{2B}$AR expression under many pathological conditions [15–17], such as hypoxia, inflammation and cancer, which may indicate the critical role of A$_{2B}$AR in many diseases.

For example, adenosine concentration has been reported to increase 10-fold in patients with septic shock [18]. Hypoxia-inducible factor 1 (HIF-1α) has been reported to up-regulate $A_{2B}AR$ expression on activated macrophages [19]. Lan et al. [20] found that hypoxia increased expression of $A_{2B}AR$ in human breast cancer cells through the transcriptional activity of HIF-1α. The discovery that $A_{2B}AR$ expression is significantly increased by HIF-1α strongly suggested its involvement in cancer promotion [20–23]. In addition to its role in tumor growth, inhibition of $A_{2B}AR$ genetically or pharmacologically dramatically decreased lung metastasis after implantation of breast cancer cells into the mammary fat pad of immunodeficient mice [20]. It has also been recently shown that bladder urothelial carcinoma expresses high levels of $A_{2B}AR$, which is suggested to be associated with a poor patient prognosis [24]. A tissue microarray of 232 breast cancer samples, that included 66 triple negative breast cancer cases suggest that $A_{2B}AR$ could serve as a prognostic biomarker and a potential therapeutic target [25]. Kasama et al. [6] showed that $A_{2B}AR$ controls cellular proliferation via HIF-1α activation, indicating that $A_{2B}AR$ may be a key regulator of tumoral progression in oral squamous cell carcinoma. Thus, the $A_{2B}AR$ is consistently and convincingly demonstrated to be involved in tumor cell proliferation, metastasis, angiogenesis, and immune suppression. Furthermore, the $A_{2B}AR$ and A_3AR seem to be the only AR subtypes that are expressed in significantly higher levels in cancer tissues in comparison to normal adjacent tissues, similar to several other GPCRs [6,8,26–28].

Although all four ARs are reported to be involved in cancer progression [16,29–31], the other three ARs have been shown both to be pro- and anti-tumoral [16]. For example, both pro- and anti-tumoral effects have been reported for the A_1AR [16]. Targeting $A_{2A}AR$ has been considered a double-edged sword [16,32]. It has been suggested that adenosine accumulation in the tumor microenvironment facilitates tumor growth through the inhibition of effector T cells and natural killer (NK) cells [33], and inhibition of $A_{2A}AR$ alone was found to be sufficient to establish anti-tumor immunity and protect against metastasis in various mouse models of cancer [33]. However, $A_{2A}AR$ deletion does not inhibit the growth of all tumor types and might have the opposite effect. For example, an increased tumor growth rate of both B16F10 melanoma and MB49 bladder carcinomas has been observed in $A_{2A}AR$ knockout (KO) mice [5]. Blocking $A_{2B}AR$ action might have advantages over the $A_{2A}AR$ as a cancer therapeutic target. Cekic et al. [5] showed that AR antagonist theophylline slowed the growth of MB49 bladder and 4T1 breast tumors in mice and reduced breast cancer cell metastasis from mammary fat to the lung via the $A_{2B}AR$, but not the $A_{2A}AR$, based on experiments using $A_{2A}AR$ or $A_{2B}AR$ KO mice. The role of A_3AR has been investigated in various cancer cell types with contrasting results, i.e., both pro- and anti-proliferative, as well as pro-apoptotic and anti-apoptotic effects [15]. Both A_3AR agonists and antagonists have been considered for anti-cancer agents, although only A_3AR agonists have progressed in clinical trials [28].

Recent advances in the signaling and function of the $A_{2B}AR$ [17,32,34,35] and the availability of selective ligands [36–38], have greatly facilitated understanding of the role of $A_{2B}AR$ in cancer progression and the rationale for the development of $A_{2B}AR$ antagonists as anti-tumor drugs. In this review, we first describe the distribution, signaling, agonists, and antagonists of the $A_{2B}AR$. We then discuss the role of the $A_{2B}AR$ in the progression of various types of cancers, and the rationale of using $A_{2B}AR$ antagonists in cancer therapy.

2. $A_{2B}AR$ Distribution and Expression

In rats, $A_{2B}AR$ mRNA was detected at various levels in all tissues studied [39]. In mice, by replacing exon 1 of the A_{2B} gene with a reporter construct containing β-gal, mouse tissue-specific activation of the A_{2B} gene promoter was conveniently determined in various organs and specific cells within those organs, with the primary site of expression being the vasculature [40]. Yang et al. [40] found that mouse smooth muscle cells, endothelial cells and macrophages exhibit high $A_{2B}AR$ expression levels. The high level of $A_{2B}AR$ expression in endothelial cells suggests a potential role in angiogenesis. In human primary cells, $A_{2B}AR$ has been found in endothelial cells, mast cells, dendritic cells, macrophages, and neutrophils [17,41]. High expression levels in dendritic cells and macrophages

indicate a possible role in modulation of immunity. In human cancer tissues, $A_{2B}AR$ expression levels were found to be higher than in adjacent normal tissues [6,8,24,26,27]. High levels of $A_{2B}AR$ have been suggested to be associated with worse prognosis in bladder urothelial carcinoma [24]. Mittal et al. [7] suggested that high $A_{2B}AR$ expression is associated with worse prognoses in triple-negative breast cancer (TNBC). In a TNBC mouse model, $A_{2B}AR$ activation increased metastasis [42], while $A_{2B}AR$ antagonism in mouse models reduced the tumor burden by immune mechanisms and action on tumor cells. The high $A_{2B}AR$ expression has also been found in many human tumor cell lines, such as PC3 prostate, T24 bladder, 1321N1 astrocytoma [35], U373MG astrocytoma [43], MDA-MB-231 breast [20], Jurkat T cells [44], BON-1 pancreatic and KRJ-I intestinal [45], A375 melanoma [46], and THP-1 human monocytes [47]. The high expression of the $A_{2B}AR$ in those cancer cells indicates its potential role in cancer progression. In a glioblastoma cell line derived from a mouse line containing spatially expressed $A_{2B}AR$, this receptor is highly upregulated leading to proliferation, angiogenesis and invasiveness [48]. Mouse KO of CD73, which forms adenosine locally from adenosine 5'-monophosphate (AMP), reduced $A_{2B}AR$ signaling in the glioblastoma, to decrease pathogenesis and increase sensitivity to chemotherapy. $A_{2B}AR$ expression was also demonstrated in human lung epithelial cells [49]. Consistent with the high $A_{2B}AR$ expression in bladder cancer and breast cancer cells, Cekic et al. [5] showed that $A_{2B}AR$ antagonists delayed the growth of bladder and breast tumors and reduced lung metastasis. Lan et al. [20] found that genetic or pharmacological inhibition of $A_{2B}AR$ expression or activity dramatically impaired tumor initiation and lung metastasis in mice. Thus, high $A_{2B}AR$ expression is related to tumor growth and metastasis, and therefore $A_{2B}AR$ antagonists are potential therapeutic agents for various types of cancers including lung cancer.

3. $A_{2B}AR$ Signaling

Classical $A_{2B}AR$ signaling has been initially and primarily demonstrated in Chinese hamster ovary (CHO) cells expressing the recombinant human $A_{2B}AR$ [50–52]. $A_{2B}AR$ activation leads to dissociation of the $G\alpha s$ and $G\beta\gamma$ subunits and subsequent activation of the adenylyl cyclases, which in turn hydrolyze intracellular ATP into cyclic AMP (cAMP), which activates protein kinase A (PKA) and many downstream signaling molecules. The Gs-cAMP-PKA axis is an important $A_{2B}AR$-mediated signaling pathway. For example, Xu et al. [53] found that $A_{2B}AR$-mediated cAMP is both necessary and sufficient to suppress interferon-γ (IFN-γ)-mediated immune responses. Jing et al. [54] showed that $A_{2B}AR$ activation in hematopoietic stem cells induced chemokine (C-X-C motif) ligand 8 (CXCL8, interleukin 8) production via cAMP-PKA signaling and mediated hematopoiesis. In addition to PKA, cAMP also activates 'exchange protein directly activated by cAMP' (EPAC), another important signaling molecule related to cell migration and angiogenesis [55]. In CHO cells expressing the recombinant human $A_{2B}AR$, the nonselective AR agonist NECA 3 activated cAMP response element-binding protein (CREB) and P38 (a mitogen-activated protein kinase, MAPK) but not Akt (protein kinase B). Extracellular signal-regulated kinase 1/2 (ERK1/2) and GTPase Rap1 were blocked by PKA inhibitor H89 [52]. Phosphorylation of Akt and ERK1/2 was blocked by a phosphoinositide 3-kinase (PI3K) inhibitor, wortmannin. Thus, $A_{2B}AR$ activating various downstream MAPKs may be via different signaling pathways. Although PKA-independent in CHO cells, Rap1 activation seems PKA-dependent in human embryonic kidney (HEK)293 cells [56]. The coupling of $A_{2B}AR$ to β-arrestin signaling has also been reported [37,57].

Most of the early studies on $A_{2B}AR$ signaling utilized CHO or HEK293 cells transfected with recombinant human $A_{2B}AR$ [51,52]. However, in various types of cells endogenously expressing $A_{2B}AR$, the receptor was able to couple to either Gi or Gs, depending on the cell type and downstream signaling pathway measured [35]. For example, $A_{2B}AR$ agonist NECA stimulates ERK1/2 phosphorylation via $G\alpha i$ in T24 bladder cancer cells [35], but via $G\alpha s$ in CHO cells [52]. The $G\alpha i$ inhibitor pertussis toxin, but not $G\alpha q$ KO, diminished NECA-stimulated ERK1/2 activity suggesting the involvement of $G\alpha i$ rather than $G\alpha q$ [35]. $A_{2B}AR$ downregulates ERK1/2 activity via $G\alpha s$ in 1321N1 astrocytoma cells [35] and in MDA-MB-231 breast cancer cells [58]. ERK1/2 reduction in MDA-MB-231 cells was triggered by

an $A_{2B}AR$ agonist and forskolin, but abolished by the PKA inhibitor H89, suggesting an important role for the cAMP-PKA pathway in controlling ERK1/2 activity in MDA-MB-231 cells. $A_{2B}AR$-mediated intracellular calcium mobilization in T24 cells was mainly via Gi, although Gs may also play a minor role, but Gq is not involved [35]. Thus, it is conceivable that in many cases the predominant $A_{2B}AR$ coupling is through Gαi rather than Gαs. Many important $A_{2B}AR$ functions from primary cells or tissues have recently been related to the PI3K-Akt and Ras-related protein (RAP)1B-EPAC pathways [59–63]. However, it has not been extensively explored whether those signaling molecules are actually downstream of $A_{2B}AR$-mediated Gαi or Gαs proteins. The $A_{2B}AR$-mediated major signaling pathways are illustrated in Figure 1.


Figure 1. A_{2B} adenosine receptor (AR) signaling in mammalian cells and in the tumor microenvironment, as explained in the text. The three G proteins shown act through either G α, e.g., on cyclic AMP (cAMP), or G β, γ subunits, e.g., on phosphoinositide 3-kinase (PI3K). Protein kinase A (PKA) has either a stimulatory or inhibitory effect on extracellular signal-regulated kinase 1/2 (ERK1/2). For more detail see: [15,35,49,56,58]. For effects on specific immune cells, see [17,32].

4. $A_{2B}AR$ Agonists and Antagonists as Pharmacological Tools

Although numerous antagonists and a few agonists for the $A_{2B}AR$ have been reported, in this section we focus on the agonists and antagonists that are commercially available as pharmacological tools and those in clinical trials for cancer patients (Table 1). In addition to selective antagonists and agonists, various specialized pharmacological tools can be used to characterize $A_{2B}AR$ and its activity. Radiolabelled compounds are used to investigate $A_{2B}AR$ binding activity including both tritiated ligands and ^{18}F-labeled compounds for positron emission tomography [64,65]. Ligands that have been tritiated for $A_{2B}AR$ binding experiments are: agonists 3 and 8; antagonists 13, 21, 22a, and ZM241,385 (structure not shown). Fluorescent antagonists of high affinity at the $A_{2B}AR$ were recently reported [66,67]. $A_{2B}AR$ allosteric modulators have been reported but not extensively characterized [36].

There are two major classes of $A_{2B}AR$ agonists that are commercially available (Figure 2). The adenosine derivatives include adenosine, NECA and CPCA 4, which are considered as full and balanced

agonists and often used as standard $A_{2B}AR$ agonists albeit nonselective [37,68]. The non-adenosine 3,5-dicyanopyridine class of $A_{2B}AR$ agonists that are commercially available include BAY60-6583 **8**, LUF5834 **7** and BAY68-4986 (A_1AR agonist Capadenoson **6**). BAY60-6583 is an $A_{2B}AR$-selective agonist but shows variable agonist E_{max} and potencies in different types of cells and tissues ([35,37]). Partial and biased agonists for the $A_{2B}AR$ have been reported [34,35,37,69,70]. In cAMP accumulation assays, 5′-substituted nucleosides NECA and CPCA, and non-adenosine agonists BAY60-6583 and BAY68-4986 are all full agonists in cells overexpressing the recombinant human $A_{2B}AR$. In calcium mobilization, ERK1/2 phosphorylation and β-arrestin translocation, only 5′-substituted adenosine analogs CPCA and NECA are full agonists. A quantitative operational model characterized BAY60-6583 as an ERK1/2-biased agonist and N^6-substituted agonists as biased against calcium and β-arrestin pathways. Interestingly, a partial $A_{2B}AR$ agonist BAY60-6583 behaved as an $A_{2B}AR$ antagonist in MIN-6 mouse pancreatic β cells expressing low $A_{2B}AR$ levels, to induce insulin release [37]. It remains to be determined whether BAY60-6583 behaves as a partial agonist or an antagonist in other cell types endogenously expressing low levels of the $A_{2B}AR$.

$A_{2B}AR$ expression levels often determine the potency and E_{max} of a given $A_{2B}AR$ agonist. BAY60-6583 was found to be a partial agonist in stimulating cAMP accumulation in several cell types endogenously expressing the $A_{2B}AR$ [37]. For example, in an assay of cAMP accumulation in HEK293 cells endogenously expressing the $A_{2B}AR$, the EC_{50} and agonist E_{max} values of BAY60-6583 are 242 nM and 73%, respectively. However, in HEK293 cells overexpressing the recombinant $A_{2B}AR$, the EC_{50} and E_{max} of BAY60-6583 are 6.1 nM and 102%, respectively [37]. BAY60-6583 did not show any agonist activity in stimulating calcium mobilization or ERK1/2 phosphorylation in T24 bladder cancer cells. BAY60-6583 also did not show any agonist activity in stimulating calcium transients in HEK293 cells, although it showed a robust effect in stimulating cAMP accumulation and ERK1/2 activity. LUF5834 has been reported as a nonselective $A_{2B}AR$ agonist showing an EC_{50} of 12 nM in cAMP accumulation and an agonist E_{max} of 74% in comparison with NECA (E_{max} = 100%) [71]. Using CHO cells overexpressing the human $A_{2B}AR$, Baltos et al. (2017) [70] found that the A_1AR agonist BAY68-4986 shows potent $A_{2B}AR$ agonist activity in stimulating cAMP accumulation, with an EC_{50} of 1.1 nM. However, when tested in cAMP accumulation in HEK293 cells endogenously expressing the $A_{2B}AR$, BAY68-4986 showed an EC_{50} of 500 nM and E_{max} of 95% (Gao and Jacobson, unpublished data). Thus, for all nucleoside and non-nucleoside $A_{2B}AR$ agonists commercially available, only the partial agonist BAY60-6583 is $A_{2B}AR$ selective, which may show agonist activity in some signaling pathways, and antagonist properties in other signaling events [37]. Full agonists selective for $A_{2B}AR$ are not yet available. Future efforts could be the development of selective and full agonists for $A_{2B}AR$, in order to have a full range of $A_{2B}AR$ efficacies for studying cell proliferation, angiogenesis, metastasis and immune suppression.

The structures and potencies of the commercially available antagonists as pharmacological tools are listed in Figure 2 and Table 1, respectively. The first selective $A_{2B}AR$ antagonists were reported by [72], which were xanthine derivatives, and currently there are chemically diverse heterocyclic selective $A_{2B}AR$ antagonists, such as recently reported LAS101053 **25**, AB928 **26** and ISAM140 **27** [3,36]. Commercially available $A_{2B}AR$ antagonists as pharmacological tools include 8-arylxanthine derivatives MRS1754 **13**, MRS1706 **14**, GS6201 **18**, PSB-1115 **21**, PSB-603 **22a** and PSB-0788 **23**. Recently, an alkylxanthine with a picomolar affinity at the human $A_{2B}AR$, PSB-1901 **22b**, was reported [73]. Antagonists that are in clinical trials (AB928 **26**, PBF-1129 and theophylline **11**) will be discussed in Section 9.

Table 1. Binding affinity (K_i, nM) or functional potency (EC_{50}, nM; E_{max} as %) of commercially available $A_{2B}AR$ agonists and antagonists as pharmacological tools and $A_{2B}AR$ antagonists in clinical trials for cancer patients. Refer to Figure 2 for structures. K_i (nM) or EC_{50} (E_{max}, %)

Compound	A_1	A_{2A}	A_{2B}	A_3	Reference
Agonists					
1, Adenosine [a]	310	700	24,000	290	[68]
			4620 [c] (97%)		[37]
3, NECA [b]	14	20	1900	25	[38]
3, NECA [a]	12	60	104 (100%)	11	[71]
4, CPCA	1.9[b]	50[b]	267 [c] (102%)	108 [b]	[37]
6, BAY68-4986 [a] (Capadenoson)	0.66	1400	1.1 (93%)	2400	[70]
			522 [c,d] (95%)		
7, LUF5834	2.6 [b]	28 [b]	12 [a] (74%)	538 [b]	[71]
8, BAY60-6583 [b]	390	>10,000	110	220	[38]
			242 [c] (73%)		[37]
			6.1 [e] (102%)		[37]
Antagonists					
11, Theophylline [b]	6200	1710	7850	22,300	
12, Caffeine [b]	44,900	9560	33,800	13,300	[38]
13, MRS1754 [b]	403	503	1.7	570	[38]
14, MRS1706 [b]	157	112	1.4	230	[38]
18, GS6201 [b] (CVT-6833)	1940	3280	22	1070	[74]
21, PSB-1115 [b]	>10,000	3790	53.4	>10,000	[38]
22a, PSB-603 [b]	>10,000	>10,000	0.55	>1000	[38]
22b, PSB-1901 [b]	>1000	>1000	0.060	>1000	[73]
23, PSB-0788 [b]	2240	333	0.39	>1000	[38]
27, LAS101057 [b]	>10,000	2500	24	>10,000	[75]
26, AB928 [b]	64	1.5	2.0	489	[76]
27, ISAM140[b]	>10,000	>10,000	0.55	>1000	[77]
PBF-1129	nd	nd	nd	nd	

[a] EC_{50} values (nM) from cAMP assays. [b] K_i values (nM) from radioligand binding. [c] EC_{50} values (nM) from cAMP assays in human embryonic kidney (HEK)293 cells endogenously expressing the $A_{2B}AR$. [d] unpublished data. [e] The EC_{50} and E_{max} values of Bay60-6583 stimulated cAMP accumulation in HEK293 cells expressing the recombinant human $A_{2B}AR$ [37]; Percentages shown in the A_{2B} column represent the agonist E_{max} in comparison to NECA as 100%. nd, not disclosed.

Figure 2. Chemical structures of both commercially available and literature-reported $A_{2B}AR$ agonists (1–10) and antagonists (11–27) as pharmacological tools and an $A_{2A}AR/A_{2B}AR$ mixed antagonist (26) in a clinical trial for cancer treatment. For more detail, see [36,37].

5. $A_{2B}AR$ in Cell Proliferation and Tumor Growth

$A_{2B}AR$ activation can promote proliferation of multiple types of cancer cells and growth of solid tumors. Activation of the $A_{2B}AR$ by BAY 60–6583 was shown to stimulate both proliferation and migration of MDA-MB-231 cells [78]. The $A_{2B}AR$-mediated effects were blocked by an $A_{2B}AR$ antagonist GS-6201. Wei et al. [1] found the $A_{2B}AR$ to be the most highly expressed AR in several human prostate cancer cell lines, including PC-3, and $A_{2B}AR$ activation promotes cell proliferation and

decreases cell apoptosis. An $A_{2B}AR$-selective antagonist PSB-603 decreased proliferation of prostate cancer cell lines [4,79], and colon cancer cells [21]. Activation of the $A_{2B}AR$ with agonist BAY 60-6583 increased tumor growth in a mouse model of melanoma [10]. In a model of bladder cancer, inhibition of tumor growth by the non-selective antagonist theophylline was demonstrated to be mediated by $A_{2B}AR$ but not $A_{2A}AR$ blockade [5]. $A_{2B}AR$ selective antagonist ATL801 also inhibited growth of MB49 bladder and 4T1 breast tumor volume [5] and melanoma in mice [10]. Stagg et al. [80] showed that $A_{2B}AR$ activation promoted 4T1.2 tumor-cell chemotaxis in vitro and metastasis in vivo. High $A_{2B}AR$ expression levels have also been found in hepatocellular carcinoma [27]. It has been suggested that high $A_{2B}AR$ levels are generally associated with worse prognosis or poor survival [7,17].

The results from $A_{2B}AR$ blockade with antagonists were consistent with those from genetic knockdown and KO of the $A_{2B}AR$ in various animal models of solid tumors [5,6,9], further confirming the critical role of this receptor in cancer cell proliferation and growth.

The specific mechanisms related to $A_{2B}AR$-mediated proliferation of various cancer cells and growth of different types of tumors have not been extensively and systematically explored. As it has been suggested that different agonists may bind in different modes and induce different $A_{2B}AR$ conformational changes [81], together with the recent finding that $A_{2B}AR$ may couple variably to at least three G proteins in different cell types, it is possible that each agonist may activate a particular mix of signaling cascades in a specific cell type, or the same agonist may activate different signaling pathways in other cell types [35]. Thus, the signaling mechanisms related to $A_{2B}AR$-mediated cell proliferation may be diverse in different types of cancers. Nevertheless, multiple studies have shown the importance of several signaling pathways related to $A_{2B}AR$ activation and the subsequent release of various cytokines and growth factors, which eventually led to cancer cell proliferation. MAPK signaling is involved in multiple cellular processes and is often active in cancer cells, promoting proliferation and metastasis [82]. $A_{2B}AR$ was demonstrated to couple to all three types of MAPKs [52], the extracellular signal-regulated kinases (ERK1/2), the stress-activated protein kinases P38 and the c-jun N-terminal kinase (JNK). The cAMP-EPAC pathway and ERK1/2 phosphorylation are known to be involved in $A_{2B}AR$-mediated proliferation of some endothelial cells [55,83]. Limm et al., [61] showed that PKC, but not cAMP or Ca^{2+}, is involved in 5′-methylthioadenosine (2)-induced and $A_{2B}AR$-mediated melanoma cell proliferation. Forskolin can mimic adenosine-induced proliferation of MDA-MB-231 breast cancer cells, suggesting that Gs-cAMP signaling is involved, although it is not clear whether PKA or EPAC is the downstream mediator. Recent evidence correlates the $A_{2B}AR$-mediated cAMP/PKA and MAPK/ERK pathway activation with the epithelial-mesenchymal transition in lung cancer cells [49]. $A_{2B}AR$ has been shown to activate the PI3K-Akt pathway [52], which is known to induce cell proliferation and protects against apoptosis in many cancer cell types. The $A_{2B}AR$-mediated PI3K-Akt pathway has been shown to be critical for proliferation of glioblastoma stem cells [84]. The importance of Akt signaling in cell survival has been demonstrated in many cell types. However, it remains to be investigated whether the $A_{2B}AR$-mediated PI3K-Akt pathway is downstream of $G\alpha i$, $G\alpha s$ or both.

6. $A_{2B}AR$ and Tumor Metastasis

$A_{2B}AR$ activation plays a critical role in cell motility and migration, which are part of the multi-step process of metastasis [8,56,85]. Adenosine binding to $A_{2B}AR$ on tumor cells was found to enhance their metastatic capability [56,86]. It was reported that the $A_{2B}AR$ has higher expression in metastatic versus non-metastatic derived colorectal cancer cell lines [21]. $A_{2B}AR$ activation has been shown to enhance tumor cell chemotaxis and lung metastasis in animal models of breast cancer and melanoma [5,7,80]. This is consistent with $A_{2B}AR$ agonist-induced metastasis, $A_{2B}AR$-selective antagonists and genetic knockdown with shRNA suppressed lung metastasis [5,7,87].

The mechanisms behind $A_{2B}AR$-mediated cell migration and metastasis have been explored [56]. $A_{2B}AR$-mediated cell motility and metastasis is related to the PKA-dependent suppression of Rap1B, a Rho member of the Ras superfamily of small GTPases that activate MAP kinases [56]. It was found

that $A_{2B}AR$ activation may delay Rap1B prenylation in breast, lung, and pancreatic cancer cell lines, and suggested that $A_{2B}AR$ inhibition may be an effective method to prevent metastasis. Similarly, Wilson et al. [88] found that another Gs-coupled GPCR family, the β-adrenergic receptors, suppresses Rap1B prenylation via a PKA-dependent mechanism and promotes the metastatic phenotype in MDA-MB-231 breast cancer cells. Desmet et al. [87] suggested that the enhanced metastasis may involve $A_{2B}AR$-increased gene expression of a key metastatic transcription factor, Fos-related antigen-1 (Fra-1), the expression level of which is associated with increased cell motility and invasion [89,90]. Fra-1 is regulated by ERK, and its overexpression is associated with a poor clinical outcome [91]. Fra-1 and $A_{2B}AR$ positively correlate at the mRNA level, and it was shown using chromatin immunoprecipition (ChIP) experiments that Fra-1 binds the promoter of the $A_{2B}AR$ gene in human breast cancer cells [87]. Ou et al. [59] discovered that hypoxia, as well as extracellular ATP, causes a reversible increase in the centrosome-nucleus distance and reduced cell motility through the $A_{2B}AR$ and specifically activates the Epac1/RapGef3 pathway. Epac1 is critically involved, and Rap1B is important in the relative positioning of the centrosome and nucleus, which is related to cell motility and migration.

7. $A_{2B}AR$ and Angiogenesis

Tumor growth is enhanced by angiogenesis, the formation of new blood vessels, which involves the migration, differentiation and growth of endothelial cells inside the blood vessels. Adenosine signaling plays an important role in angiogenesis. Adenosine has been reported to promote angiogenic responses via all four AR subtypes [28,92–94]. The endothelial cells express high levels of the $A_{2B}AR$ suggesting its potentially critical role in promoting angiogenesis. $A_{2B}AR$ stimulation promotes the production of angiogenic cytokines by mast cells [9] and dendritic cells [95]. It has been suggested that adenosine increases endothelial cell proliferation, chemotaxis and capillary tube formation [83,96]. $A_{2B}AR$ activation has also been shown to stimulate production of vascular endothelial growth factor (VEGF), basic fibroblast growth factor and insulin-like growth factor-1 (IGF1) by human microvascular endothelial (HMEC)-1 cells [23]. Adenosine was demonstrated to promote VEGF production in rat myocardial myoblasts [97] and in macrophages from C57BL/6 mice [98] It has been demonstrated that AR stimulation could increase VEGF production five-fold in tumor-associated CD45$^+$ immune cells, an effect that is not observed in CD45$^+$ cells from $A_{2B}AR$ KO mice [96] The $A_{2B}AR$ induces production of VEGF [23,96,99] and interleukin (IL)-8 in human melanoma cells [46], which are essential for tumor angiogenesis. Bay60-6583, a selective $A_{2B}AR$ agonist, was demonstrated to induce in tumor expression of VEGF-A [100]. $A_{2B}AR$ inhibition by a selective antagonist PSB-1115 21 significantly decreased tumor growth by blocking angiogenesis and increasing T cells numbers within the tumor microenvironment.

Multiple signaling molecules have been found to be related to $A_{2B}AR$-mediated angiogenesis. Du et al. [101] suggested the $A_{2B}AR$ activation-driven angiogenesis is via cAMP-PKA-CREB mediated VEGF production and PI3K/Akt-dependent upregulation of endothelial nitric oxide synthase (eNOS) in HMEC-1 cells. Ryzhov et al. [97] suggested that VEGF appears to be stimulated by a mechanism involving the transcription factor JunB downstream of $A_{2B}AR$-mediated PLC-Rap1-MEK activation. Fang and Olah [55] showed that cyclic AMP-dependent, protein kinase A-independent activation of ERK1/2 following AR stimulation in human umbilical vein endothelial cells was via Epac1.

8. $A_{2B}AR$ and Immunity

It has been well documented that cancer cells can escape from anti-tumor immune surveillance especially under conditions with impaired immunity. Adenosine has demonstrated its role as an important modulator of immune cell functions at least in part via its action at the $A_{2B}AR$ [17,32,41]. $A_{2B}AR$ activation is known to suppress IFN-γ-enhanced expression of major histocompatibility complex class II (MHC-II) transactivator [53,102]. In addition to the well-described roles of CD73 and CD39, adenosine deaminase is known to control the local adenosine concentration, and this enzyme also binds to the $A_{2B}AR$ [103] Adenosine deaminase deficiency is one of the serious immune diseases which is due to the increased adenosine concentration and subsequently suppressed immune responses. Thus, in

addition to its direct effects on metastasis, proliferation and angiogenesis, the $A_{2B}AR$ can have a direct or an indirect role on cancer progression via modulation of the immune system. The role of the $A_{2B}AR$ in cell immunity was mostly neglected until recently partly due to adenosine having a low $A_{2B}AR$ affinity [11,12], although early findings indicated that $A_{2B}AR$ was the AR subtype responsible for the immune suppressive function of T cells, macrophages and dendritic cells [11,17,41]. Also, early work on CD26/DPP4 (dipeptidyl peptidase 4), a T cell surface antigen that cleaves various bioactive peptides, mainly focused on its role in T cells [104,105] that highly express the $A_{2A}AR$ [106–108]. More recently, in addition to CD39 and CD73, the importance of $A_{2B}AR$ and DPP4 in dendritic cells and macrophages also gained appreciation [47]. DPP4 has been identified as one of the macrophage-related gene signatures predicative of increased risk in gliomas [109]. DPP4 inhibitor vildagliptin has been reported to suppress lung cancer growth via a macrophage-mediated mechanism [110]. Considering the increased adenosine concentration and increased $A_{2B}AR$ expression in the tumor microenvironment [17,31,100] together with the high expression levels of both $A_{2B}AR$ and DPP4 in macrophages and dendritic cells, growing evidence suggests a critical role of $A_{2B}AR$ together with CD39 and CD73 in modulating cancer progression at least in part via immune suppression. Furthermore, DPP4 physically associates with adenosine deaminase, which controls adenosine concentration and binds to the $A_{2B}AR$. Thus, $A_{2B}AR$ blockade may enhance the function of immune cells [17,31,41].

$A_{2A}AR$ has been shown to be critical in regulating toll-like receptor (TLR)-induced cytokine production. However, a recent study utilizing macrophages isolated from $A_{2B}AR$ KO mice showed that adenosine elicits IL-6 production from macrophages via the $A_{2B}AR$ [19]. IFN-γ upregulates $A_{2B}AR$ expression on macrophages resulting in an increased responsiveness of macrophages to the stimulatory effects of NECA [111]. The pharmacologic inhibition or the genetic deletion of the $A_{2B}AR$ results in a hyperinflammatory response to TLR ligation, similar to IFN-γ treatment of macrophages, suggesting the NECA-mediated effect is via $A_{2B}AR$, but not $A_{2A}AR$ [111]. The role of $A_{2B}AR$ in regulating dendritic cell function has been defined using $A_{2B}AR$ KO mice and selective agonists and antagonists for $A_{2B}AR$ [17,41]. In mice bearing MB49 and/or 4T1 tumors, Cekic et al. [5] demonstrated that selective blockade of $A_{2B}AR$ resulted in a C-X-C chemokine receptor 3 (CXCR3)-dependent reduction of tumor growth and lung metastases from breast tumors through enhancement of dendritic cell activation. Inhibition of $A_{2B}AR$ activation by PSB-603 was shown to suppress regulatory T cell (Treg) differentiation and IL-10 production, without affecting effector T cell activation measured by IL-2 production and CD25 expression [112]. $A_{2B}AR$ was also suggested to modulate the phenotype of bone marrow-derived dendritic cells. $A_{2B}AR$ activation impairs MHC-II transcription in IFN-γ-stimulated cells [113,114]. MHC-II expression is required for CD4$^+$ T cell anti-tumor responses, and loss of MHC-II is associated with aggressiveness of colorectal cancer and decreased levels of tumor-infiltrating lymphocytes [115]. Shi et al. [116] also reported that both major MHC-II transactivator (CIITA) and MHC-II are decreased in highly metastatic cancer cells. Thus, $A_{2B}AR$ blockade has the potential to enhance anti-tumor immunity in cancers where tumor-infiltrating lymphocytes and MHC-II levels are decreased.

The specific signaling pathways related to $A_{2B}AR$-mediated immune suppression have been explored. Xu et al. [53] found that $A_{2B}AR$-mediated cAMP is both necessary and sufficient to suppress the IFN-γ-mediated immune response. Figueiredo et al. [117] showed that cAMP accumulation induced by $A_{2B}AR$ activation is important to inhibit dendritic cell activation and to evade the immune response in infected mice. In human monocytes, it has been suggested that $A_{2B}AR$-triggered cAMP accumulation inhibits the immune response by lowering the amount of MHC class I and class II molecules [118]. $A_{2B}AR$-induced cAMP accumulation was also found to reduce STAT1 phosphorylation and impair its binding to the CIITA promoter while fostering synthesis of TGF-β, known to antagonize MHC-II transactivation [113,114]. Iannone et al. [10] showed that melanoma-bearing mice treated with the selective $A_{2B}AR$ agonist BAY60-6583 had increased melanoma growth, which was associated with higher levels of immune regulatory mediators IL-10 and monocyte chemoattractant protein 1 and accumulation of tumor-associated CD11b+ and Gr1+ cells and myeloid-derived suppressor cells.

Depletion of CD11b+Gr1+ cells completely reversed the pro-tumor activity of BAY60-6583. Inhibition of $A_{2B}AR$ with PSB-1115 reversed immune suppression in the tumor microenvironment, leading to a significant delay in melanoma growth. The authors suggest that the antitumor activity of PSB-1115 relies on its ability to lower accumulation of tumor-infiltrating myeloid-derived suppressor cells (MDSCs) and restore an efficient antitumor T cell response.

9. $A_{2B}AR$ Antagonists as Novel Anticancer Agents

As described above, $A_{2B}AR$ activation induces tumor proliferation, growth of solid tumor, tumor angiogenesis, tumor cell invasion and metastasis, and immune suppression. Thus, $A_{2B}AR$ blockade holds great promise as an anti-cancer therapy. For example, $A_{2B}AR$ inhibition by the antagonist PSB-1115 was shown to decrease tumor metastasis of $CD73^+$ melanoma cells and mammary carcinoma cells [7] Iannone et al. [10] observed that PSB-1115 delayed tumor growth and enhanced the anti-tumor activity of dacarzabine, a drug currently used in metastatic melanoma.

Cekic et al. [5] demonstrated that the antitumor effect of theophylline occurs via the $A_{2B}AR$ rather $A_{2A}AR$, based on a study using A_{2A} and $A_{2B}AR$ KO mice. Nevertheless, simultaneous antagonism of both subtypes has been proposed to be possibly synergistic against some types of tumors [17,32], although it is not clear whether the blockade of both $A_{2A}AR$ and $A_{2B}AR$ could also produce more adverse effects than either subtype separately.

Antagonists in clinical trials for cancer patients (ClinicalTrials.gov NCT Identifier) include the mixed $A_{2A}AR/A_{2B}AR$ antagonist AB928 26 (Phase 1, lung cancer, 03846310; Phase 1, breast and ovarian cancer, 03719326; Phase 1, gastrointestinal cancer, 03720678; Phase 1, advanced cancer, 03629756), PBF-1129 (structure not disclosed; Phase 1, non-small cell lung cancer, 03274479) and theophylline 11 (see below). The first dual-acting $A_{2A}AR/A_{2B}AR$ antagonist AB928 is being tested clinically in multiple arms in combination with pegylated liposomal doxorubicin, nanoparticle albumin-bound paclitaxel, or a PI3K-γ inhibitor. AB928 has exhibited excellent safety, PK, and PD profiles in a Phase 1 clinical trial in healthy volunteers and is currently being evaluated in patients with non-small cell lung cancer, breast cancer, ovarian cancer, colorectal and six other types of cancers (clinicaltrials.gov). One of the cancer immunotherapy drugs, AB122, a fully human immunoglobulin G4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1), will be tried in combination with AB928. AB928 was able to produce maximal AR blockade assessed as a function of NECA-stimulated pCREB induction in peripheral blood CD8+ T cells [3]. AB928 was shown to relieve adenosine-mediated immune suppression [76]. Combining AR inhibition with AB928 and chemotherapy results in greater immune activation and tumor control.

A phase I trial of the selective $A_{2B}AR$ antagonist PBF-1129 (structure not disclosed) in patients with advanced non-small cell lung cancer is being conducted. PBF-1129 is being administered in a dose escalation study of tolerability without other therapy.

Theophylline is a nonselective AR antagonist, which was tested for anticancer efficacy in two previous clinical trials (incidentally, as an inhibitor of intracellular cAMP in chronic lymphocytic leukemia, Phase 2, 00003808; a withdrawn trial in combination with an allogeneic tumor cell-vaccine (gp96-Ig vaccine) and oxygen therapy, which lowers adenosine levels [119], in non-small cell lung cancer, Phase 1, 01799161). The first theophylline trial description did not even reference AR antagonism, but there was a correlation found between in vitro apoptosis in leukemia cells and clinical response in a subset of patients [120]. Theophylline in combination prednisone and dextromethorphan has also been in a clinical trial (Phase 1, 01017939) for patients with metastatic castration-resistant prostate cancer. Aminophylline, a salt of theophylline, in combination with Bacillus Calmette-Guerin has been in a trial (early Phase 1, 01240824) for patients with bladder cancer. However, it should be noted that theophylline is nonselective and may block all four ARs.

10. Summary

$A_{2B}AR$ signaling is a major pathway contributing to cancer cell proliferation and solid tumor growth, angiogenesis and metastasis, and immune suppression. Thus, $A_{2B}AR$ antagonists are potentially a novel anticancer therapy, either in combination with other anticancer drugs or as a mono-therapy. Several $A_{2B}AR$ antagonists are now in clinical trials for patients with various types of cancers. The nonselective $A_{2B}AR$ antagonist, theophylline, in combination with other anticancer drugs has been evaluated in patients with bladder cancer and prostate cancer. Dual acting $A_{2A}AR/A_{2B}AR$ antagonist AB928 has exhibited excellent safety, PK, and PD profiles in a Phase 1 clinical trial in healthy volunteers and is currently being evaluated in patients with non-small cell lung cancer, breast cancer and ovarian cancer. $A_{2B}AR$ selective antagonist PBF-1129 is also in clinical trial for patients with non-small cell lung cancer. Thus, $A_{2B}AR$ antagonism is a promising direction for the development of new cancer therapeutics.

References

1. Wei, Q.; Costanzi, S.; Liu, Q.Z.; Gao, Z.G.; Jacobson, K.A. Activation of the $P2Y_1$ receptor induces apoptosis and inhibits proliferation of prostate cancer cells. *Biochem. Pharmacol.* **2011**, *82*, 418–425. [CrossRef] [PubMed]

2. Burnstock, G.; Di Virgilio, F. Purinergic signalling and cancer. *Purinergic Signal.* **2013**, *9*, 491–540. [CrossRef] [PubMed]

3. Seitz, L.; Jin, L.; Leleti, M.; Ashok, D.; Jeffrey, J.; Rieger, A.; Tiessen, R.G.; Arold, G.; Tan, J.B.L.; Powers, J.P.; et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. *Invest. New Drugs* **2019**, *37*, 711–721. [CrossRef] [PubMed]

4. Wei, Q.; Costanzi, S.; Balasubramanian, R.; Gao, Z.G.; Jacobson, K.A. A_{2B} adenosine receptor blockade inhibits growth of prostate cancer cells. *Purinergic Signal.* **2013**, *9*, 271–280. [CrossRef] [PubMed]

5. Cekic, C.; Sag, D.; Li, Y.; Theodorescu, D.; Strieter, R.M.; Linden, J. Adenosine A_{2B} receptor blockade slows growth of bladder and breast tumors. *J. Immunol.* **2012**, *188*, 198–205. [CrossRef] [PubMed]

6. Kasama, H.; Sakamoto, Y.; Kasamatsu, A.; Okamoto, A.; Koyama, T.; Minakawa, Y.; Ogawara, K.; Yokoe, H.; Shiiba, M.; Tanzawa, H.; et al. Adenosine A_{2b} receptor promotes progression of human oral cancer. *Clin. Cancer Res.* **2016**, *22*, 158–166. [CrossRef]

7. Mittal, D.; Sinha, D.; Barkauskas, D.; Young, A.; Kalimutho, M.; Stannard, K.; Caramia, F.; Haibe-Kains, B.; Stagg, J.; Khanna, K.K.; et al. Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. *Cancer Res.* **2016**, *76*, 4372–4382. [CrossRef]

8. Sepúlveda, C.; Palomo, I.; Fuentes, E. Role of adenosine A_{2b} receptor overexpression in tumor progression. *Life Sci.* **2016**, *166*, 92–99. [CrossRef]

9. Ryzhov, S.; Novitskiy, S.V.; Zaynagetdinov, R.; Goldstein, A.E.; Carbone, D.P.; Biaggioni, I.; Dikov, M.M.; Feoktistov, I. Host A_{2B} adenosine receptors promote carcinoma growth. *Neoplasia* **2008**, *10*, 987–995. [CrossRef]

10. Iannone, R.; Miele, L.; Maiolino, P.; Pinto, A.; Morello, S. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. *Neoplasia* **2013**, *15*, 1400–1409. [CrossRef]

11. Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Linden, J.; Müller, C.E. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—An update. *Pharmacol. Rev.* **2011**, *63*, 1–34. [CrossRef] [PubMed]

12. Jacobson, K.A.; Gao, Z.G. Adenosine receptors as therapeutic targets. *Nat. Rev. Drug Discov.* **2006**, *5*, 247–264. [CrossRef] [PubMed]

13. Drury, A.N.; Szent-Györgyi, A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. *J. Physiol.* **1929**, *68*, 213–237. [CrossRef] [PubMed]

14. Daly, J.W.; Butts-Lamb, P.; Padgett, W. Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines. *Cell Mol. Neurobiol.* **1983**, *3*, 69–80. [CrossRef]

15. Borea, P.A.; Gessi, S.; Merighi, S.; Varani, K. Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How does it Exert its Protective Effects? *Trends Pharmacol. Sci.* **2016**, *37*, 419–434. [CrossRef]

16. Borea, P.A.; Gessi, S.; Merighi, S.; Vincenzi, F.; Varani, K. Pharmacology of Adenosine Receptors: The State of the Art. *Physiol. Rev.* **2018**, *98*, 1591–1625. [CrossRef]

17. Cekic, C.; Linden, J. Purinergic regulation of the immune system. *Nat. Rev. Immunol.* **2016**, *16*, 177–192. [CrossRef]

18. Ramakers, B.P.; Riksen, N.P.; van der Hoeven, J.G.; Smits, P.; Pickkers, P. Modulation of innate immunity by adenosine receptor stimulation. *Shock* **2011**, *36*, 208–215. [CrossRef]

19. Philip, K.; Mills, T.W.; Davies, J.; Chen, N.Y.; Karmouty-Quintana, H.; Luo, F.; Molina, J.G.; Amione-Guerra, J.; Sinha, N.; Guha, A.; et al. HIF1A up-regulates the ADORA2B receptor on alternatively activated macrophages and contributes to pulmonary fibrosis. *FASEB J.* **2017**, *31*, 4745–4748. [CrossRef]

20. Lan, J.; Lu, H.; Samanta, D.; Salman, S.; Lu, Y.; Semenza, G.L. Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E9640–E9648. [CrossRef]

21. Ma, D.F.; Kondo, T.; Nakazawa, T.; Niu, D.F.; Mochizuki, K.; Kawasaki, T.; Yamane, T.; Katoh, R. Hypoxia-inducible adenosine A_{2B} receptor modulates proliferation of colon carcinoma cells. *Hum. Pathol.* **2010**, *41*, 1550–1557. [CrossRef] [PubMed]

22. Kong, T.; Westerman, K.A.; Faigle, M.; Eltzschig, H.K.; Colgan, S.P. HIF-dependent induction of adenosine A_{2B} receptor in hypoxia. *FASEB J.* **2006**, *20*, 2242–2250. [CrossRef] [PubMed]

23. Feoktistov, I.; Goldstein, A.E.; Ryzhov, S.; Zeng, D.; Belardinelli, L.; Voyno-Yasenetskaya, T.; Biaggioni, I. Differential expression of adenosine receptors in human endothelial cells: Role of A_{2B} receptors in angiogenic factor regulation. *Circ. Res.* **2002**, *90*, 531–538. [CrossRef] [PubMed]

24. Zhou, Y.; Chu, X.; Deng, F.; Tong, L.; Tong, G.; Yi, Y.; Liu, J.; Tang, J.; Tang, Y.; Xia, Y.; et al. The adenosine A_{2b} receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway. *Oncotarget* **2017**, *8*, 48755–48768. [CrossRef]

25. Horigome, E.; Fujieda, M.; Handa, T.; Katayama, A.; Ito, M.; Ichihara, A.; Tanaka, D.; Gombodorj, N.; Yoshiyama, S.; Yamane, A.; et al. Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A_{2b} receptor signaling. *Oncotarget* **2018**, *9*, 34554–34566. [CrossRef]

26. Li, S.; Huang, S.; Peng, S.B. Overexpression of G protein-coupled receptors in cancer cells: Involvement in tumor progression. *Int. J. Oncol.* **2005**, *27*, 1329–1339. [CrossRef]

27. Xiang, H.J.; Liu, Z.C.; Wang, D.S.; Chen, Y.; Yang, Y.L.; Dou, K.F. Adenosine A_{2b} receptor is highly expressed in human hepatocellular carcinoma. *Hepatol. Res.* **2006**, *36*, 56–60. [CrossRef]

28. Cohen, S.; Fishman, P. Targeting the A_3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. *Drug Des. Devel. Ther.* **2019**, *13*, 491–497. [CrossRef]

29. Koszałka, P.; Gołuńska, M.; Urban, A.; Stasiłojć, G.; Stanisławowski, M.; Majewski, M.; Składanowski, A.C.; Bigda, J. Specific Activation of A_3, A_{2A} and A_1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration. *PLoS ONE* **2016**, *11*, e0151420. [CrossRef]

30. Marwein, S.; Mishra, B.; Chandra, D.U.; Acharya, P.C. Recent progress of adenosine receptor modulators in the development of anticancer chemotherapeutic agents. *Curr. Pharm. Des.* **2019**, *25*, 2842–2858. [CrossRef]

31. Gorain, B.; Choudhury, H.; Yee, G.S.; Bhattamisra, S.K. Adenosine receptors as novel targets for the treatment of various cancers. *Curr. Pharm. Des.* **2019**. [Epub ahead of print]. [CrossRef] [PubMed]

32. Allard, B.; Beavis, P.A.; Darcy, P.K.; Stagg, J. Immunosuppressive activities of adenosine in cancer. *Curr. Opin. Pharmacol.* **2016**, *29*, 7–16. [CrossRef] [PubMed]

33. Cekic, C.; Linden, J. Adenosine A_{2A} receptors intrinsically regulate CD8[+] T cells in the tumor microenvironment. *Cancer Res.* **2014**, *74*, 7239–7249. [CrossRef] [PubMed]

34. Vecchio, E.A.; White, P.J.; May, L.T. The adenosine A_{2B} G protein-coupled receptor: Recent advances and therapeutic implications. *Pharmacol. Ther.* **2019**, *198*, 20–33. [CrossRef]

35. Gao, Z.G.; Inoue, A.; Jacobson, K.A. On the G protein-coupling selectivity of the native A_{2B} adenosine receptor. *Biochem. Pharmacol.* **2018**, *151*, 201–213. [CrossRef]

36. Müller, C.E.; Baqi, Y.; Hinz, S.; Namasivayam, V. Chapter 6, Medicinal chemistry of A_{2B} adenosine receptors. *Adenosine Recept.* **2018**, *34*, 137–168.

37. Gao, Z.G.; Balasubramanian, R.; Kiselev, E.; Wei, Q.; Jacobson, K.A. Probing biased/partial agonism at the G protein-coupled A_{2B} adenosine receptor. *Biochem. Pharmacol.* **2014**, *90*, 297–306. [CrossRef]

38. Alnouri, M.W.; Jepards, S.; Casari, A.; Schiedel, A.C.; Hinz, S.; Müller, C.E. Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors. *Purinergic Signal.* **2015**, *11*, 389–407. [CrossRef]

39. Dixon, A.K.; Gubitz, A.K.; Sirinathsinghji, D.J.; Richardson, P.J.; Freeman, T.C. Tissue distribution of adenosine receptor mRNAs in the rat. *Br. J. Pharmacol.* **1996**, *118*, 1461–1468. [CrossRef]

40. Yang, D.; Zhang, Y.; Nguyen, H.G.; Koupenova, M.; Chauhan, A.K.; Makitalo, M.; Jones, M.R.; St Hilaire, C.; Seldin, D.C.; Toselli, P.; et al. The A_{2B} adenosine receptor protects against inflammation and excessive vascular adhesion. *J. Clin. Invest.* **2006**, *116*, 1913–1923. [CrossRef]

41. Haskó, G.; Csóka, B.; Németh, Z.H.; Vizi, E.S.; Pacher, P. A_{2B} adenosine receptors in immunity and inflammation. *Trends Immunol.* **2009**, *30*, 263–270. [CrossRef] [PubMed]

42. Neumann, C.A.; Levine, K.; Oesterreich, S. Targeting adenosine receptor 2B in triple negative breast cancer. *J. Cancer Metastasis Treat.* **2018**, *4*, 13. [CrossRef]

43. Fiebich, B.L.; Biber, K.; Gyufko, K.; Berger, M.; Bauer, J.; van Calker, D. Adenosine A2b receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. *J. Neurochem.* **1996**, *66*, 1426–1431. [CrossRef] [PubMed]

44. Nonaka, H.; Ichimura, M.; Takeda, M.; Nonaka, Y.; Shimada, J.; Suzuki, F.; Yamaguchi, K.; Kase, H. KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist. *Eur. J. Pharmacol.* **1994**, *267*, 335–341. [CrossRef]

45. Kalhan, A.; Gharibi, B.; Vazquez, M.; Jasani, B.; Neal, J.; Kidd, M.; Modlin, I.M.; Pfragner, R.; Rees, D.A.; Ham, J. Adenosine A_{2A} and A_{2B} receptor expression in neuroendocrine tumours: Potential targets for therapy. *Purinergic Signal.* **2012**, *8*, 265–274. [CrossRef] [PubMed]

46. Merighi, S.; Simioni, C.; Gessi, S.; Varani, K.; Mirandola, P.; Tabrizi, M.A.; Baraldi, P.G.; Borea, P.A. A_{2B} and A_3 adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. *Neoplasia* **2009**, *11*, 1064–1073. [CrossRef] [PubMed]

47. Zhong, J.; Rao, X.; Deiuliis, J.; Braunstein, Z.; Narula, V.; Hazey, J.; Mikami, D.; Needleman, B.; Satoskar, A.R.; Rajagopalan, S. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. *Diabetes* **2013**, *62*, 149–157. [CrossRef]

48. Yan, A.; Joachims, M.L.; Thompson, L.F.; Miller, A.D.; Canoll, P.D.; Bynoe, M.S. CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A_{2B} Adenosine Receptor Signaling. *J. Neurosci.* **2019**, *39*, 4387–4402. [CrossRef]

49. Giacomelli, C.; Daniele, S.; Romei, C.; Tavanti, L.; Neri, T.; Piano, I.; Celi, A.; Martini, C.; Trincavelli, M.L. The A_{2B} adenosine receptor modulates the epithelial–mesenchymal transition through the balance of cAMP/PKA and MAPK/ERK pathway activation in human epithelial lung cells. *Front Pharmacol.* **2018**, *9*, 54. [CrossRef]

50. Rivkees, S.A.; Reppert, S.M. RFL9 encodes an A2b-adenosine receptor. *Mol. Endocrinol.* **1992**, *6*, 1598–1604.

51. Pierce, K.D.; Furlong, T.J.; Selbie, L.A.; Shine, J. Molecular cloning and expression of an adenosine A_{2b} receptor from human brain. *Biochem. Biophys. Res. Commun.* **1992**, *187*, 86–93. [CrossRef]

52. Schulte, G.; Fredholm, B.B. The G_s-coupled adenosine A_{2B} receptor recruits divergent pathways to regulate ERK1/2 and p38. *Exp. Cell Res.* **2003**, *290*, 168–176. [CrossRef]

53. Xu, Y.; Ravid, K.; Smith, B.D. Major histocompatibility class II transactivator expression in smooth muscle cells from A_{2b} adenosine receptor knock-out mice: Cross-talk between the adenosine and interferon-gamma signaling. *J. Biol. Chem.* **2008**, *283*, 14213–14220. [CrossRef] [PubMed]

54. Jing, L.; Tamplin, O.J.; Chen, M.J.; Deng, Q.; Patterson, S.; Kim, P.G.; Durand, E.M.; McNeil, A.; Green, J.M.; Matsuura, S.; et al. Adenosine signaling promotes hematopoietic stem and progenitor cell emergence. *J. Exp. Med.* **2015**, *212*, 649–663. [CrossRef] [PubMed]

55. Fang, Y.; Olah, M.E. Cyclic AMP-dependent.; protein kinase A-independent activation of extracellular signal-regulated kinase 1/2 following adenosine receptor stimulation in human umbilical vein endothelial cells: Role of exchange protein activated by cAMP 1 (Epac1). *J. Pharmacol. Exp. Ther.* **2007**, *322*, 1189–1200. [CrossRef] [PubMed]

56. Ntantie, E.; Gonyo, P.; Lorimer, E.L.; Hauser, A.D.; Schuld, N.; McAllister, D.; Kalyanaraman, B.; Dwinell, M.B.; Auchampach, J.A.; Williams, C.L. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. *Sci. Signal.* **2013**, *6*, 39. [CrossRef] [PubMed]

57. Mundell, S.J.; Olah, M.E.; Panettieri, R.A.; Benovic, J.L.; Penn, R.B. Regulation of G protein-coupled receptor-adenylyl cyclase responsiveness in human airway smooth muscle by exogenous and autocrine adenosine. *Am. J. Respir. Cell Mol. Biol.* **2001**, *24*, 155–163. [CrossRef]

58. Koussémou, M.; Lorenz, K.; Klotz, K.N. The A_{2B} adenosine receptor in MDA-MB-231 breast cancer cells diminishes ERK1/2 phosphorylation by activation of MAPK-phosphatase-1. *PLoS ONE* **2018**, *13*, e0202914. [CrossRef]

59. Ou, Y.; Chan, G.; Zuo, J.; Rattner, J.B.; van der Hoorn, F.A. Purinergic A_{2b} Receptor Activation by Extracellular Cues Affects Positioning of the Centrosome and Nucleus and Causes Reduced Cell Migration. *J. Biol. Chem.* **2016**, *291*, 15388–15403. [CrossRef]

60. Phosri, S.; Arieyawong, A.; Bunrukchai, K.; Parichatikanond, W.; Nishimura, A.; Nishida, M.; Mangmool, S. Stimulation of Adenosine A_{2B} Receptor Inhibits Endothelin-1-Induced Cardiac Fibroblast Proliferation and α-Smooth Muscle Actin Synthesis Through the cAMP/Epac/PI3K/Akt-Signaling Pathway. *Front Pharmacol.* **2017**, *8*, 428. [CrossRef]

61. Lim, B.; Jung, K.; Gwon, Y.; Oh, J.G.; Roh, J.I.; Hong, S.H.; Kho, C.; Park, W.J.; Lee, H.W.; Bae, J.W.; et al. Cardioprotective role of APIP in myocardial infarction through ADORA2B. *Cell Death Dis.* **2019**, *10*, 511. [CrossRef] [PubMed]

62. Ni, Y.; Liang, D.; Tian, Y.; Kron, I.L.; French, B.A.; Yang, Z. Infarct-Sparing Effect of Adenosine A_{2B} Receptor Agonist Is Primarily Due to Its Action on Splenic Leukocytes Via a PI3K/Akt/IL-10 Pathway. *J. Surg. Res.* **2018**, *232*, 442–449. [CrossRef] [PubMed]

63. Shen, Y.; Tang, G.; Gao, P.; Zhang, B.; Xiao, H.; Si, L.Y. Activation of adenosine A2b receptor attenuates high glucose-induced apoptosis in H9C2 cells via PI3K/Akt signaling. *In Vitro Cell. Dev. Biol. Anim.* **2018**, *54*, 384–391. [CrossRef] [PubMed]

64. Hinz, S.; Alnouri, W.M.; Pleiss, U.; Müller, C.E. Tritium-labeled agonists as tools for studying adenosine A_{2B} receptors. *Purinergic Signal.* **2018**, *14*, 223–233. [CrossRef] [PubMed]

65. Lindemann, M.; Hinz, S.; Deuther-Conrad, W.; Namasivayam, V.; Dukic-Stefanovic, S.; Teodoro, R.; Toussaint, M.; Kranz, M.; Juhl, C.; Steinbach, J.; et al. Radiosynthesis and in vivo evaluation of a fluorine-18 labeled pyrazine based radioligand for PET imaging of the adenosine A_{2B} receptor. *Bioorg. Med. Chem.* **2018**, *26*, 4650–4663. [CrossRef] [PubMed]

66. Barresi, E.; Giacomelli, C.; Daniele, S.; Tonazzini, I.; Robello, M.; Salerno, S.; Piano, I.; Cosimelli, B.; Greco, G.; Da Settimo, F.; et al. Novel fluorescent triazinobenzimidazole derivatives as probes for labelling human A_1 and A_{2B} adenosine receptor subtypes. *Bioorg. Med. Chem.* **2018**, *26*, 5885–5895. [CrossRef]

67. Köse, M.; Gollos, S.; Karcz, T.; Fiene, A.; Heisig, F.; Behrenswerth, A.; Kieć-Kononowicz, K.; Namasivayam, V.; Müller, C.E. Fluorescent-Labeled Selective Adenosine A_{2B} Receptor Antagonist Enables Competition Binding Assay by Flow Cytometry. *J. Med. Chem.* **2018**, *61*, 4301–4316. [CrossRef]

68. Fredholm, B.B.; Irenius, E.; Kull, B.; Schulte, G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. *Biochem. Pharmacol.* **2001**, *61*, 443–448. [CrossRef]

69. Hinz, S.; Lacher, S.K.; Seibt, B.F.; Müller, C.E. BAY60-6583 acts as a partial agonist at adenosine A_{2B} receptors. *J. Pharmacol. Exp. Ther.* **2014**, *349*, 427–436. [CrossRef]

70. Baltos, J.A.; Vecchio, E.A.; Harris, M.A.; Qin, C.X.; Ritchie, R.H.; Christopoulos, A.; White, P.J.; May, L.T. Capadenoson, a clinically trialed partial adenosine A_1 receptor agonist, can stimulate adenosine A_{2B} receptor biased agonism. *Biochem. Pharmacol.* **2017**, *135*, 79–89. [CrossRef]

71. Beukers, M.W.; Chang, L.C.; von Frijtag Drabbe Künzel, J.K.; Mulder-Krieger, T.; Spanjersberg, R.F.; Brussee, J.; IJzerman, A.P. New, non-adenosine, high-potency agonists for the human adenosine A_{2B} receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. *J. Med. Chem.* **2004**, *47*, 3707–3709. [CrossRef] [PubMed]

72. Kim, Y.C.; Ji, X.D.; Melman, N.; Linden, J.; Jacobson, K.A. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A$_{2B}$ adenosine receptors. *J. Med. Chem.* **2000**, *43*, 1165–1172. [CrossRef] [PubMed]

73. Jiang, J.; Seel, C.J.; Temirak, A.; Namasivayam, V.; Arridu, A.; Schabikowski, J.; Baqi, Y.; Hinz, S.; Hockemeyer, J.; Müller, C.E. A$_{2B}$ adenosine receptor antagonists with picomolar potency. *J. Med. Chem.* **2019**, *62*, 4032–4055. [CrossRef] [PubMed]

74. Elzein, E.; Kalla, R.V.; Li, X.; Perry, T.; Gimbel, A.; Zeng, D.; Lustig, D.; Leung, K.; Zablocki, J. Discovery of a novel A$_{2B}$ adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. *J. Med. Chem.* **2008**, *51*, 2267–2278. [CrossRef]

75. Eastwood, P.; Esteve, C.; González, J.; Fonquerna, S.; Aiguadé, J.; Carranco, I.; Doménech, T.; Aparici, M.; Miralpeix, M.; Albertí, J.; et al. Discovery of LAS101057: A potent, selective, and orally efficacious A$_{2B}$ adenosine receptor antagonist. *ACS Med. Chem. Lett.* **2011**, *2*, 213–218. [CrossRef]

76. Walters, M.J.; Piovesan, D.; Tan, J.B.; DiRenzo, D.; Yin, F.; Miles, D.; Leleti, M.R.; Park, T.; Soriano, F.; Sharif, E.; et al. Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control. *Cancer Res.* **2018**, *78*, 5556.

77. El Maatougui, A.; Azuaje, J.; González-Gómez, M.; Miguez, G.; Crespo, A.; Carbajales, C.; Escalante, L.; García-Mera, X.; Gutiérrez-de-Terán, H.; Sotelo, E. Discovery of potent and highly selective A$_{2B}$ adenosine receptor antagonist chemotypes. *J. Med. Chem.* **2016**, *59*, 1967–1983. [CrossRef]

78. Fernandez-Gallardo, M.; González-Ramírez, R.; Sandoval, A.; Felix, R.; Monjaraz, E. Adenosine Stimulate Proliferation and Migration in Triple Negative Breast Cancer Cells. *PLoS ONE* **2016**, *11*, e0167445. [CrossRef]

79. Vecchio, E.A.; Tan, C.Y.; Gregory, K.J.; Christopoulos, A.; White, P.J.; May, L.T. Ligand-Independent Adenosine A$_{2B}$ receptor constitutive activity as a promoter of prostate cancer cell proliferation. *J. Pharmacol. Exp. Ther.* **2016**, *357*, 36–44. [CrossRef]

80. Stagg, J.; Divisekera, U.; McLaughlin, N.; Sharkey, J.; Pommey, S.; Denoyer, D.; Dwyer, K.M.; Smyth, M.J. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 1547–1552. [CrossRef]

81. Thimm, D.; Schiedel, A.C.; Sherbiny, F.F.; Hinz, S.; Hochheiser, K.; Bertarelli, D.C.; Maass, A.; Müller, C.E. Ligand-specific binding and activation of the human adenosine A$_{2B}$ receptor. *Biochemistry* **2013**, *52*, 726–740. [CrossRef] [PubMed]

82. Loi, S.; Dushyanthen, S.; Beavis, P.A.; Salgado, R.; Denkert, C.; Savas, P.; Combs, S.; Rimm, D.L.; Giltnane, J.M.; Estrada, M.V.; et al. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. *Clin. Cancer Res.* **2019**, *25*, 1437. [CrossRef] [PubMed]

83. Grant, M.B.; Davis, M.I.; Caballero, S.; Feoktistov, I.; Biaggioni, I.; Belardinelli, L. Proliferation, migration, and ERK activation in human retinal endothelial cells through A$_{2B}$ adenosine receptor stimulation. *Invest. Ophthalmol Vis. Sci.* **2001**, *42*, 2068–2073. [PubMed]

84. Liu, T.Z.; Wang, X.; Bai, Y.F.; Liao, H.Z.; Qiu, S.C.; Yang, Y.Q.; Yan, X.H.; Chen, J.; Guo, H.B.; Zhang, S.Z. The HIF-2alpha dependent induction of PAP and adenosine synthesis regulates glioblastoma stem cell function through the A$_{2B}$ adenosine receptor. *Int. J. Biochem. Cell Biol.* **2014**, *49*, 8–16. [CrossRef] [PubMed]

85. Sun, Y.; Hu, W.; Yu, X.; Liu, Z.; Tarran, R.; Ravid, K.; Huang, P. Actinin-1 binds to the C-terminus of A$_{2B}$ adenosine receptor (A$_{2B}$AR) and enhances A$_{2B}$AR cell-surface expression. *Biochem. J.* **2016**, *473*, 2179–2186. [CrossRef]

86. Rodrigues, S.; De Wever, O.; Bruyneel, E.; Rooney, R.J.; Gespach, C. Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. *Oncogene* **2007**, *26*, 5615–5625. [CrossRef]

87. Desmet, C.J.; Gallenne, T.; Prieur, A.; Reyal, F.; Visser, N.L.; Wittner, B.S.; Smit, M.A.; Geiger, T.R.; Laoukili, J.; Iskit, S.; et al. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 5139–5144. [CrossRef]

88. Wilson, J.M.; Lorimer, E.; Tyburski, M.D.; Williams, C.L. β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells. *Cancer Biol. Ther.* **2015**, *16*, 1364–1374. [CrossRef]

89. Belguise, K.; Kersual, N.; Galtier, F.; Chalbos, D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. *Oncogene* **2005**, *24*, 1434–1444. [CrossRef]

90. Adiseshaiah, P.; Lindner, D.J.; Kalvakolanu, D.V.; Reddy, S.P. FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. *Cancer Res.* **2007**, *67*, 6204–6211. [CrossRef]

91. Zhao, C.; Qiao, Y.; Jonsson, P.; Wang, J.; Xu, L.; Rouhi, P.; Sinha, I.; Cao, Y.; Williams, C.; Dahlman-Wright, K. Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. *Cancer Res.* **2014**, *74*, 3983–3994. [CrossRef] [PubMed]

92. Clark, A.N.; Youkey, R.; Liu, X.; Jia, L.; Blatt, R.; Day, Y.J.; Sullivan, G.W.; Linden, J.; Tucker, A.L. A_1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. *Circ. Res.* **2007**, *101*, 1130–1138. [CrossRef] [PubMed]

93. Feoktistov, I.; Feoktistov, I.; Ryzhov, S.; Zhong, H.; Goldstein, A.E.; Matafonov, A.; Zeng, D.; Biaggioni, I. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A_{2B} angiogenic phenotype. *Hypertension* **2004**, *44*, 649–654. [CrossRef] [PubMed]

94. Adair, T.H. Growth regulation of the vascular system: An emerging role for adenosine. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2005**, *289*, R283–R296. [CrossRef]

95. Novitskiy, S.V.; Ryzhov, S.; Zaynagetdinov, R.; Goldstein, A.E.; Huang, Y.; Tikhomirov, O.Y.; Blackburn, M.R.; Biaggioni, I.; Carbone, D.P.; Feoktistov, I.; et al. Adenosine receptors in regulation of dendritic cell differentiation and function. *Blood* **2008**, *112*, 1822–1831. [CrossRef]

96. Acurio, J.; Troncoso, F.; Bertoglia, P.; Salomon, C.; Aguayo, C.; Sobrevia, L.; Escudero, C. Potential role of A_{2B} adenosine receptors on proliferation/migration of fetal endothelium derived from preeclamptic pregnancies. *Biomed. Res. Int.* **2014**, *2014*, 274507.

97. Gu, J.W.; Ito, B.R.; Sartin, A.; Frascogna, N.; Moore, M.; Adair, T.H. Inhibition of adenosine kinase induces expression of VEGF mRNA and protein in myocardial myoblasts. *Am. J. Physiol. Heart Circ. Physiol.* **2000**, *279*, H2116–H2123. [CrossRef]

98. Leibovich, S.J.; Chen, J.F.; Pinhal-Enfield, G.; Belem, P.C.; Elson, G.; Rosania, A.; Ramanathan, M.; Montesinos, C.; Jacobson, M.; Schwarzschild, M.A.; et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A_{2A} receptor agonists and endotoxin. *Am. J. Pathol.* **2002**, *160*, 2231–2244. [CrossRef]

99. Ryzhov, S.; Biktasova, A.; Goldstein, A.E.; Zhang, Q.; Biaggioni, I.; Dikov, M.M.; Feoktistov, I. Role of JunB in adenosine A_{2B} receptor-mediated vascular endothelial growth factor production. *Mol. Pharmacol.* **2014**, *85*, 62–73. [CrossRef]

100. Sorrentino, C.; Morello, S. Role of adenosine in tumor progression: Focus on A_{2B} receptor as potential therapeutic target. *J. Cancer Metastasis Treat.* **2017**, *3*, 127–138. [CrossRef]

101. Du, X.; Ou, X.; Song, T.; Zhang, W.; Cong, F.; Zhang, S.; Xiong, Y. Adenosine A_{2B} receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells. *Exp. Biol. Med. (Maywood)* **2015**, *240*, 1472–1479. [CrossRef] [PubMed]

102. Xaus, J.; Mirabet, M.; Lloberas, J.; Soler, C.; Lluis, C.; Franco, R.; Celada, A. IFN-gamma up-regulates the A_{2B} adenosine receptor expression in macrophages: A mechanism of macrophage deactivation. *J. Immunol.* **1999**, *162*, 3607–3614. [PubMed]

103. Herrera, C.; Casadó, V.; Ciruela, F.; Schofield, P.; Mallol, J.; Lluis, C.; Franco, R. Adenosine A_{2B} receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. *Mol. Pharmacol.* **2001**, *59*, 127–134. [CrossRef] [PubMed]

104. Dong, R.P.; Kameoka, J.; Hegen, M.; Tanaka, T.; Xu, Y.; Schlossman, S.F.; Morimoto, C. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. *J. Immunol.* **1996**, *156*, 1349–1355. [PubMed]

105. Morimoto, C.; Schlossman, S.F. The structure and function of CD26 in the T-cell immune response. *Immunol. Rev.* **1998**, *161*, 55–70. [CrossRef]

106. Hoskin, D.W.; Mader, J.S.; Furlong, S.J.; Conrad, D.M.; Blay, J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). *Int. J. Oncol.* **2008**, *32*, 527–535. [CrossRef]

107. Kjaergaard, J.; Hatfield, S.; Jones, G.; Ohta, A.; Sitkovsky, M. A_{2A} Adenosine Receptor Gene Deletion or Synthetic A_{2A} Antagonist Liberate Tumor-Reactive CD8[+] T Cells from Tumor-Induced Immunosuppression. *J. Immunol.* **2018**, *201*, 782–791. [CrossRef]

108. Erdmann, A.A.; Gao, Z.G.; Jung, U.; Foley, J.; Borenstein, T.; Jacobson, K.A.; Fowler, D.H. Activation of Th1 and Tc1 cell adenosine A$_{2A}$ receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. *Blood* **2005**, *105*, 4707–4714. [CrossRef]

109. Sun, X.; Liu, X.; Xia, M.; Shao, Y.; Zhang, X.D. Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas. *J. Transl. Med.* **2019**, *17*, 159. [CrossRef]

110. Jang, J.H.; Janker, F.; De Meester, I.; Arni, S.; Borgeaud, N.; Yamada, Y.; Gil Bazo, I.; Weder, W.; Jungraithmayr, W. The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity. *Carcinogenesis* **2019**, *40*, 324–334. [CrossRef]

111. Cohen, H.B.; Ward, A.; Hamidzadeh, K.; Ravid, K.; Mosser, D.M. IFN-γ Prevents Adenosine Receptor (A2bR) Upregulation to Sustain the Macrophage Activation Response. *J. Immunol.* **2015**, *195*, 3828–3837. [CrossRef] [PubMed]

112. Nakatsukasa, H.; Tsukimoto, M.; Harada, H.; Kojima, S. Adenosine A$_{2B}$ receptor antagonist suppresses differentiation to regulatory T cells without suppressing activation of T cells. *Biochem. Biophys. Res. Commun.* **2011**, *409*, 114–119. [CrossRef] [PubMed]

113. Fang, M.; Xia, J.; Wu, X.; Kong, H.; Wang, H.; Xie, W.; Xu, Y. Adenosine signaling inhibits CIITA-mediated MHC class II transactivation in lung fibroblast cells. *Eur. J. Immunol.* **2013**, *43*, 2162–2173. [CrossRef] [PubMed]

114. Xia, J.; Fang, M.; Wu, X.; Yang, Y.; Yu, L.; Xu, H.; Kong, H.; Tan, Q.; Wang, H.; Xie, W.; et al. A$_{2b}$ adenosine signaling represses CIITA transcription via an epigenetic mechanism in vascular smooth muscle cells. *Biochim. Biophys. Acta.* **2015**, *1849*, 665–676. [CrossRef] [PubMed]

115. Warabi, M.; Kitagawa, M.; Hirokawa, K. Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer: Immunohistological and histopathological analyses as compared with normal colonic mucosa and adenomas. *Pathol. Res. Pract.* **2000**, *196*, 807–815. [CrossRef]

116. Shi, B.; Vinyals, A.; Alia, P.; Broceño, C.; Chen, F.; Adrover, M.; Gelpi, C.; Price, J.E.; Fabra, A. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development. *Int. J. Biochem. Cell Biol.* **2006**, *38*, 544–562. [CrossRef]

117. Figueiredo, A.B.; Souza-Testasicca, M.C.; Mineo, T.W.P.; Afonso, L.C.C. *Leishmania amazonensis*-Induced cAMP Triggered by Adenosine A$_{2B}$ Receptor Is Important to Inhibit Dendritic Cell Activation and Evade Immune Response in Infected Mice. *Front Immunol.* **2017**, *8*, 849. [CrossRef]

118. Sciaraffia, E.; Riccomi, A.; Lindstedt, R.; Gesa, V.; Cirelli, E.; Patrizio, M.; De Magistris, M.T.; Vendetti, S. Human monocytes respond to extracellular cAMP through A$_{2A}$ and A$_{2B}$ adenosine receptors. *J. Leukoc. Biol.* **2014**, *96*, 113–122. [CrossRef]

119. Hatfield, S.M.; Sitkovsky, M. A$_{2A}$ adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer. *Curr. Opin. Pharmacol.* **2016**, *29*, 90–96. [CrossRef]

120. Wiernik, P.H.; Paietta, E.; Goloubeva, O.; Lee, S.J.; Makower, D.; Bennett, J.M.; Wade, J.L.; Ghosh, C.; Kaminer, L.S.; Pizzolo, J.; et al. Eastern Cooperative Oncology Group. Phase II study of theophylline in chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E4998). *Leukemia* **2004**, *18*, 1605–1610. [CrossRef]